Drug intelligence / Profile preview

erlotinib + gefitinib + bevacizumab

Development stage: Unknown
Lead developer: Astellas Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy targeting both the epidermal growth factor receptor (EGFR) pathway with tyrosine kinase inhibitors (erlotinib and gefitinib) and the vascular endothelial growth factor (VEGF) pathway with a monoclonal antibody (bevacizumab). This approach aims to simultaneously inhibit tumor cell proliferation and angiogenesis, particularly in EGFR-mutated non-small cell lung cancer.

Targets

EGFR (Epidermal growth factor receptor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on erlotinib + gefitinib + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + gefitinib + bevacizumab.

Explore the full profile